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Nourishing America’s Preemies
Scientists Confront the Challenges of IV Feeding
STEPHEN AUSMUS (D2848-3)

Each year, more than a half-million infants are born

prematurely in the United States. Many of these preemies,

particularly those whose tiny digestive systems are simply
too underdeveloped to handle mother’s milk or infant formula, may need to be nourished exclusively via intravenous
feeding, known as “total parenteral nutrition,” or TPN.
TPN solutions, usually administered at the hospital for
anywhere from a few days to a month or more, provide essential nutrients broken down into a very basic form. This
liquid is gently and continuously infused into the infant’s
bloodstream, completely bypassing the digestive tract.
“TPN helps save the lives of newborns and supports
their growth and development, especially of the brain,”
says Douglas G. Burrin, an Agricultural Research Service
physiologist at the Children’s Nutrition Research Center in
Houston, Texas, and a faculty member at Baylor College
of Medicine, also in Houston.
But preemies who are on TPN for longer than 2 weeks
may develop complications that might affect their health
later in life. Since 1998, Burrin and colleague Barbara
Stoll, who is also with the nutrition center and the college
faculty, have worked with teams of scientists in the United
States and abroad to discover more about the unwanted side
effects of TPN and to develop new, safe, effective ways to
prevent these unintended consequences or, at the very least,
to minimize their impact.
The TPN-linked problems that their research targets
include poor control of blood sugar, slowed growth of the
digestive tract, and onset of a constellation of disorders
referred to as “parenteral nutrition-associated liver disease.”
In these investigations, Burrin and colleagues use piglets
as their laboratory animal model.

Why Piglets?

Nutrition researchers worldwide recognize that the pig
digestive tract is very similar to
that of humans. Also, the size
and body composition, that is,
the amount of fat and amount of
lean tissue, of an infant piglet “are
typically comparable to those of
a human preemie,” says Burrin.
“Infant lab mice or newborn lab
rats are simply too small for this
research.”

At the Children’s Nutrition Research Center in Houston, Texas, ARS physiologist
and professor of pediatrics Doug Burrin (left) and associate professor of pediatrics
Darryl Hadsell examine a microscope image of pancreatic beta cells obtained from
piglets fed by total parenteral nutrition.

Does TPN Increase Risk of Insulin Resistance?

In 2005, scientists elsewhere suggested an association between
premature birth and increased risk of insulin resistance, a disorder
common in type 2 diabetics.
A 2010 study by Burrin, Stoll, and others brought TPN into this
picture. Their research provided the first evidence, in a newborn-labanimal model, of a significant association between TPN feeding and
several indicators of insulin resistance.
In people, and in piglets, insulin—a hormone—largely controls the
amount of sugar (glucose) in the bloodstream. Insulin is produced
exclusively by unique “beta cells” in the pancreas. As it circulates
through the body, insulin triggers cells to remove glucose from blood
and use it for energy. But resistance to insulin can lead to a buildup of
unhealthy levels of glucose in the blood.
Insulin resistance was 40 percent greater in the TPN-fed piglets than
in their orally fed counterparts, the scientists found. Also of concern:
Proliferation of beta cells was 30
percent less in the TPN piglets.
“The beta cells that you produce during infancy and childhood have to last you a lifetime,”
says Burrin, “so anything that
interferes with normal beta-cell
production could be detrimental
to your later health. “

Compared to human preemies,
infant piglets are similar in size and
body composition and have similar
digestive tracts. These healthy piglets
are about an hour old.

GLP-1 Levels: How Important
Are They?

Followup research, reported
by Burrin, Stoll, and others in
2012, again indicated that insulin
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resistance was significantly greater in TPNfed piglets, compared to piglets that were
put on other feeding regimens.
In addition, the study suggested that
reduced production of GLP-1 (glucagonlike peptide 1), a hormone secreted in
the digestive tract, may help explain the
difference in insulin resistance among the
research piglets.
Previous research has shown that GLP1, a “gut hormone,” circulates through the
body and helps lessen insulin resistance.
It belongs to a class of hormones known
as “incretins.” Their insulin-regulating
role, dubbed the “incretin effect,” has led
to development of synthetic incretins now
used in treatment of type 2 diabetes.
Says Burrin, “We found that plasma
levels of GLP-1 were significantly lower
in the TPN piglets than in any of the other
piglet groups. That makes sense, given that
there was no food in the TPN piglets’ digestive tracts to stimulate secretion of GLP-1.
“We are continuing to investigate GLP-1
in our research because we think there’s
much more to be learned about it in the
context of preventing or reducing insulin
resistance in TPN infants.”
Small Doses of Bile Acid May Blunt
Liver Disease

Gut hormones were also key in a study
of a potential new approach to preventing
parenteral nutrition-associated liver disease
(PNALD).
PNALD is an umbrella term that encompasses several conditions, including
cholestasis, which results from a buildup
of excess bile acids in the liver, and steatosis, which—as its “fatty liver” nickname
implies—occurs when there is too much
fat in the liver.
There is no well-established,
science-based cure for PNALD.
In severe cases, this disease can
lead to liver failure and the need
for a liver transplant—a major
surgery that, though not new, is
still regarded as having considerable risks.
A team of Burrin, Stoll, and
coinvestigators showed that giving newborn TPN-fed piglets a
very small dose of a natural bile
acid three times a day helped
combat PNALD.

The acid, CDCA (chenodeoxycholic
acid) is one of the major bile acids that are
produced in the liver, then secreted—via the
gall bladder and bile duct—into the upper
digestive tract to help the body digest fat.
According to Burrin, the CDCA study
is the first to demonstrate the use of small
doses of this bile acid, delivered directly to
the upper digestive tract, to control PNALD
in a newborn-lab-animal model.
TPN piglets that were given CDCA
had significantly lower levels of serum
bilirubin, a biomarker of cholestasis, than
did the TPN-fed piglets that were given a
placebo. In addition, levels of serum bile
acids, which are another biomarker of cholestasis, and levels of liver triglycerides, an
indicator of steatosis, were nearly normal
in the CDCA-treated TPN piglets.
The team also found that CDCA stimulated growth of mucosa, the inner lining of
the intestine. That is significant. Explains
Burrin, “TPN often has the exact opposite
effect: It can lead to atrophy of the mucosa.”
The shriveling and shrinking of the intestine
that result can diminish the body’s ability
to digest and absorb nutrients.
The researchers are now taking a closer
look at the basic mechanisms responsible
for the beneficial effects of the CDCA regimen. CDCA’s ability—as shown in mice—
to indirectly induce secretion of key gut
hormones such as GLP-2 (glucagon-like
peptide 2) and FGF19 (fibroblast growth
factor 19) “may provide an explanation for
some of our piglet findings,” Burrin says.
For example, previous research, including that by Burrin and Stoll, has shown that
GLP-2 boosts growth and proliferation of
intestinal mucosal cells in piglets and in
adult humans. In this newer study, reported

in 2012, three factors—GLP-2 levels, better
mucosal growth, and CDCA treatment—
appeared to be interrelated. That’s because
TPN piglets that were treated with CDCA
had higher levels of GLP-2 in their plasma.
Those same piglets had better mucosal
growth than the other TPN piglets.
FGF19 may also be an important part
of the picture. In mice, FGF19 has the
protective effect of suppressing production of bile acids in the liver, in response
to signals sent from specialized bile-acidsensing cells in the gut. CDCA-treated TPN
piglets had healthier bile acid levels, and
more FGF19 in their plasma, than did the
other TPN-fed piglets.
Piglets that were not on a TPN regimen
had the highest plasma FGF19 levels. “We
regard this finding as strong evidence that
TPN suppresses secretion of FGF19, which
results in disruption of normal regulation
of bile acids. We think this suppression is
a key piece of the puzzle of why and how
TPN can cause liver disease.”
Burrin and Stoll, along with Teresa
A. Davis, Darryl L. Hadsell, and David
D. Moore, all of the nutrition center
research staff and Baylor College of
Medicine faculty, and other collaborators,
have documented their TPN findings in
peer-reviewed articles in the Journal of
Nutrition, the American Journal of Parenteral and Enteral Nutrition, the American
Journal of Physiology: Gastrointestinal
and Liver Physiology, and other scientific
publications. The American Society for
Parenteral and Enteral Nutrition, the National Institutes of Health, the American
Liver Foundation, and ARS funded the
studies.—By Marcia Wood, ARS.
This research is part of Human Nutrition, an ARS national program
(#107) described at www.nps.
ars.usda.gov.
Douglas G. Burrin is with the
USDA-ARS Children’s Nutrition
Research Center, 1100 Bates
St., Houston, TX 77030; (713)
798-7049, doug.burrin@ars.
usda.gov.
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Research instructor of pediatrics
Barbara Stoll (left) and assistant
Liwei Cui fill parenteral nutrition
bags with formulas to nourish
infant piglets.
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